Geron (GERN) Competitors $1.40 +0.01 (+0.43%) As of 09:30 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GERN vs. ALKS, LGND, BCRX, FOLD, CLDX, INVA, DVAX, MNKD, OPK, and NVAXShould you be buying Geron stock or one of its competitors? The main competitors of Geron include Alkermes (ALKS), Ligand Pharmaceuticals (LGND), BioCryst Pharmaceuticals (BCRX), Amicus Therapeutics (FOLD), Celldex Therapeutics (CLDX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), and Novavax (NVAX). These companies are all part of the "biotechnology" industry. Geron vs. Its Competitors Alkermes Ligand Pharmaceuticals BioCryst Pharmaceuticals Amicus Therapeutics Celldex Therapeutics Innoviva Dynavax Technologies MannKind OPKO Health Novavax Alkermes (NASDAQ:ALKS) and Geron (NASDAQ:GERN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, earnings, valuation and risk. Is ALKS or GERN more profitable? Alkermes has a net margin of 23.30% compared to Geron's net margin of -119.54%. Alkermes' return on equity of 27.52% beat Geron's return on equity.Company Net Margins Return on Equity Return on Assets Alkermes23.30% 27.52% 17.98% Geron -119.54%-47.86%-26.78% Does the media prefer ALKS or GERN? In the previous week, Alkermes had 8 more articles in the media than Geron. MarketBeat recorded 9 mentions for Alkermes and 1 mentions for Geron. Alkermes' average media sentiment score of 1.26 beat Geron's score of 0.00 indicating that Alkermes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alkermes 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has stronger earnings and valuation, ALKS or GERN? Alkermes has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlkermes$1.56B3.15$367.07M$2.0914.23Geron$76.99M11.55-$174.57M-$0.21-6.65 Do analysts rate ALKS or GERN? Alkermes currently has a consensus price target of $40.00, suggesting a potential upside of 34.54%. Geron has a consensus price target of $5.06, suggesting a potential upside of 262.64%. Given Geron's higher possible upside, analysts clearly believe Geron is more favorable than Alkermes.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alkermes 0 Sell rating(s) 3 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.83Geron 0 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.78 Which has more risk and volatility, ALKS or GERN? Alkermes has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500. Comparatively, Geron has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Do institutionals and insiders have more ownership in ALKS or GERN? 95.2% of Alkermes shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.4% of Alkermes shares are owned by insiders. Comparatively, 7.4% of Geron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. SummaryAlkermes beats Geron on 12 of the 16 factors compared between the two stocks. Get Geron News Delivered to You Automatically Sign up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GERN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GERN vs. The Competition Export to ExcelMetricGeronMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$889.14M$2.88B$5.50B$8.94BDividend YieldN/A2.45%5.25%4.04%P/E Ratio-6.6520.8026.9720.11Price / Sales11.55287.03426.02119.76Price / CashN/A41.1936.8257.86Price / Book3.037.487.985.56Net Income-$174.57M-$55.04M$3.16B$248.40M7 Day Performance-0.29%2.44%2.36%4.67%1 Month Performance-13.83%1.90%2.15%6.64%1 Year Performance-69.52%4.35%33.78%21.31% Geron Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GERNGeron2.8462 of 5 stars$1.40+0.4%$5.06+262.6%-69.3%$889.14M$76.99M-6.6570ALKSAlkermes4.9324 of 5 stars$28.60-0.7%$40.00+39.9%+20.6%$4.72B$1.56B13.681,800Positive NewsLGNDLigand Pharmaceuticals4.7539 of 5 stars$113.68-0.4%$146.14+28.6%+32.5%$2.19B$167.13M-15.9780BCRXBioCryst Pharmaceuticals4.4608 of 5 stars$8.96-4.3%$16.89+88.5%+36.9%$1.87B$450.71M-34.46530FOLDAmicus Therapeutics3.6799 of 5 stars$5.73-3.4%$16.22+183.1%-38.8%$1.76B$528.29M-63.66480CLDXCelldex Therapeutics3.0711 of 5 stars$20.35+0.3%$50.11+146.2%-41.3%$1.35B$7.02M-7.54150Positive NewsINVAInnoviva3.8693 of 5 stars$20.09+0.7%$55.00+173.8%+16.0%$1.26B$358.71M-19.89100DVAXDynavax Technologies4.3583 of 5 stars$9.92+0.1%$24.00+141.9%-5.3%$1.19B$277.25M-19.08350MNKDMannKind2.523 of 5 stars$3.74-0.5%$10.33+176.3%-32.8%$1.14B$297.60M37.40400Negative NewsOPKOPKO Health4.5376 of 5 stars$1.32flat$2.75+108.3%+5.4%$1.05B$713.10M-18.852,997NVAXNovavax4.488 of 5 stars$6.30-1.1%$17.00+169.8%-41.6%$1.02B$682.16M2.381,990 Related Companies and Tools Related Companies ALKS Competitors LGND Competitors BCRX Competitors FOLD Competitors CLDX Competitors INVA Competitors DVAX Competitors MNKD Competitors OPK Competitors NVAX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GERN) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredThe DOJ Just Paved the Way for Account SeizuresWashington is running out of money…And guess where they'll look next? When governments go broke, they take ...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Geron Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Geron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GERN Stock Alerts